Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
affiliate, attended, bankruptcy, Biden, Chapter, chose, Code, Consolidated, convened, critical, delisted, delisting, enjoined, entertainment, entry, explanation, harbor, hear, inconsistent, indirect, Influence, insulin, Joe, justification, mechanism, official, oral, orderly, PDUFA, permissible, personal, pharmacy, point, portion, premarket, purported, refinancing, reimport, reintroduce, reorganization, resubmission, resubmitted, sector, sought, structure, summary, Thereof, undrawn, unviable, update, valuation
Filing tables
Filing exhibits
ATXI similar filings
Filing view
External links
Exhibit 32.1
Certification of
Principal Executive Officer
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
I, Lucy Lu, M.D., Chief Executive Officer of Avenue Therapeutics, Inc. (the “Company”), in compliance with Section 906 of the Sarbanes-Oxley Act of 2002, hereby certify that, to the best of my knowledge, the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2021 (the “Report”) filed with the Securities and Exchange Commission:
• | Fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
• | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
/s/ Lucy Lu, M.D. | |
Lucy Lu, M.D. | |
President, Chief Executive Officer and Director | |
(Principal Executive Officer) | |
May 17, 2021 |